Cetera Investment Advisers Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cetera Investment Advisers lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 10,575 shares of the biopharmaceutical company’s stock after purchasing an additional 1,336 shares during the quarter. Cetera Investment Advisers’ holdings in Regeneron Pharmaceuticals were worth $6,707,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Marietta Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after acquiring an additional 2,501 shares during the period. Pamalican Asset Management Ltd purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $4,915,000. Rhenman & Partners Asset Management AB boosted its holdings in Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock worth $30,956,000 after acquiring an additional 4,457 shares during the period. GAMMA Investing LLC boosted its holdings in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after acquiring an additional 814,713 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $558.87 on Friday. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a market cap of $60.34 billion, a P/E ratio of 14.23, a P/E/G ratio of 2.05 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The stock’s 50 day simple moving average is $538.05 and its 200 day simple moving average is $604.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the business earned $9.55 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was down 3.7% on a year-over-year basis. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.96%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target for the company. in a report on Friday. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a report on Friday, April 25th. Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. Finally, Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $837.61.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.